387 related articles for article (PubMed ID: 25167700)
1. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
2. Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites.
Pomázi A; Ambrus R; Sipos P; Szabó-Révész P
J Pharm Biomed Anal; 2011 Sep; 56(2):183-90. PubMed ID: 21652159
[TBL] [Abstract][Full Text] [Related]
3. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
4. Aerodynamic properties and in silico deposition of meloxicam potassium incorporated in a carrier-free DPI pulmonary system.
Chvatal A; Farkas Á; Balásházy I; Szabó-Révész P; Ambrus R
Int J Pharm; 2017 Mar; 520(1-2):70-78. PubMed ID: 28161667
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
6. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
7. Utilization of spray drying technique for improvement of dissolution and anti-inflammatory effect of Meloxicam.
Shazly G; Badran M; Zoheir K; Alomrani A
Pak J Pharm Sci; 2015 Jan; 28(1):103-11. PubMed ID: 25553688
[TBL] [Abstract][Full Text] [Related]
8. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
11. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
[TBL] [Abstract][Full Text] [Related]
12. Conception, preparation and properties of functional carrier particles for pulmonary drug delivery.
Odziomek M; Sosnowski TR; Gradoń L
Int J Pharm; 2012 Aug; 433(1-2):51-9. PubMed ID: 22580211
[TBL] [Abstract][Full Text] [Related]
13. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
14. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
[TBL] [Abstract][Full Text] [Related]
15. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
16. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
17. Development of extra-fine particles containing nanosized meloxicam for deep pulmonary delivery: In vitro aerodynamic and cell line measurements.
Party P; Kókai D; Burián K; Nagy A; Hopp B; Ambrus R
Eur J Pharm Sci; 2022 Sep; 176():106247. PubMed ID: 35760279
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
19. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques.
Louey MD; Van Oort M; Hickey AJ
Pharm Res; 2004 Jul; 21(7):1200-6. PubMed ID: 15290860
[TBL] [Abstract][Full Text] [Related]
20. The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles.
Gilani K; Najafabadi AR; Barghi M; Rafiee-Tehrani M
J Pharm Sci; 2005 May; 94(5):1048-59. PubMed ID: 15793812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
